Literature DB >> 21087085

Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.

Amit Joshi1, Sandeep Rajput, Chun Wang, Jun Ma, Deliang Cao.   

Abstract

Aldo-keto reductase family 1 member B10 (AKR1B10), over-expressed in multiple human cancers, might be implicated in cancer development and progression via detoxifying cytotoxic carbonyls and regulating fatty acid synthesis. In the present study, we investigated the ortholog of AKR1B10 in mice, an ideal modeling organism greatly contributing to human disease investigations. In the mouse, there are three aldo-keto reductase family 1 subfamily B (AKR1B) members, i.e., AKR1B3, AKR1B7, and AKR1B8. Among them, AKR1B8 has the highest similarity to human AKR1B10 in terms of amino acid sequence, computer-modeled structures, substrate spectra and specificity, and tissue distribution. More importantly, similar to human AKR1B10, mouse AKR1B8 associates with murine acetyl-CoA carboxylase-α and mediates fatty acid synthesis in colon cancer cells. Taken together, our data suggest that murine AKR1B8 is the ortholog of human AKR1B10.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21087085     DOI: 10.1515/BC.2010.144

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  13 in total

1.  Aldo-keto reductase family 1 member B8 is secreted via non-classical pathway.

Authors:  Zhenwang Tang; Chenglai Xia; Renbin Huang; Xiaoning Li; Wan-Chun Wang; Wangyuan Guo; Lili Duan; Weihao Luo; Deliang Cao; Di-Xian Luo
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.

Authors:  Yongzhen Liu; Jing Zhang; Hui Liu; Guiwen Guan; Ting Zhang; Leijie Wang; Xuewei Qi; Huiling Zheng; Chia-Chen Chen; Jia Liu; Deliang Cao; Fengmin Lu; Xiangmei Chen
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

3.  Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls.

Authors:  Mahavir Singh; Aniruddh Kapoor; Aruni Bhatnagar
Journal:  Chem Biol Interact       Date:  2015-01-02       Impact factor: 5.192

4.  Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice.

Authors:  Yi Shen; Jun Ma; Ruilan Yan; Hongyan Ling; Xiaoning Li; Wancai Yang; John Gao; Chenfei Huang; Yiwen Bu; Yu Cao; Yingchun He; Laxiang Wan; Xuyu Zu; Jianghua Liu; Mei Chris Huang; William F Stenson; Duan-Fang Liao; Deliang Cao
Journal:  Clin Cancer Res       Date:  2014-12-23       Impact factor: 12.531

5.  Aldo-Keto Reductases 1B in Endocrinology and Metabolism.

Authors:  Emilie Pastel; Jean-Christophe Pointud; Fanny Volat; Antoine Martinez; Anne-Marie Lefrançois-Martinez
Journal:  Front Pharmacol       Date:  2012-08-02       Impact factor: 5.810

6.  Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.

Authors:  F Xavier Ruiz; Sergio Porté; Xavier Parés; Jaume Farrés
Journal:  Front Pharmacol       Date:  2012-04-17       Impact factor: 5.810

Review 7.  Aldo-Keto Reductases 1B in Adrenal Cortex Physiology.

Authors:  Emilie Pastel; Jean-Christophe Pointud; Antoine Martinez; A Marie Lefrançois-Martinez
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-22       Impact factor: 5.555

8.  Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.

Authors:  Antoinette van Weverwijk; Nikolaos Koundouros; Marjan Iravani; Matthew Ashenden; Qiong Gao; George Poulogiannis; Ute Jungwirth; Clare M Isacke
Journal:  Nat Commun       Date:  2019-06-20       Impact factor: 14.919

9.  Impaired Barrier Function and Immunity in the Colon of Aldo-Keto Reductase 1B8 Deficient Mice.

Authors:  Xin Wang; Ramina Khoshaba; Yi Shen; Yu Cao; Minglin Lin; Yun Zhu; Zhe Cao; Duan-Fang Liao; Deliang Cao
Journal:  Front Cell Dev Biol       Date:  2021-02-12

Review 10.  Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.

Authors:  Li Huang; Rongzhang He; Weihao Luo; Yuan-Shan Zhu; Jia Li; Tan Tan; Xi Zhang; Zheng Hu; Dixian Luo
Journal:  Recent Pat Anticancer Drug Discov       Date:  2016       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.